Drug Profile
Research programme: cancer therapeutics - Rottapharm
Alternative Names: 4-oxo-fenretinideLatest Information Update: 25 Feb 2010
Price :
$50
*
At a glance
- Originator Rottapharm
- Class
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer; Neuroblastoma; Ovarian cancer
Most Recent Events
- 22 Mar 2007 Preclinical trials in Breast cancer in Italy (unspecified route)
- 22 Mar 2007 Preclinical trials in Neuroblastoma in Italy (unspecified route)
- 22 Mar 2007 Preclinical trials in Ovarian cancer in Italy (unspecified route)